Abstract | PURPOSE: METHODS AND MATERIALS: A total of 125 patients with newly diagnosed GBM were enrolled in the study, and received standard radiation therapy and daily temozolomide. All patients underwent a craniotomy and were at least 2 weeks postoperative. Radiation therapy was administered in 1.8-Gy fractions, with the clinical target volume for the primary course treated to a dose of 45 to 50.4 Gy, followed by a boost of 9 to 14.4 Gy, to a total dose of 59.4 Gy. Patients received temozolomide at 75 mg/m(2) daily throughout the course of radiation therapy. Bevacizumab was given at 10 mg/kg intravenously every 14 days, beginning a minimum of 4 weeks postoperatively. RESULTS: Of the 125 patients, 120 (96%) completed the protocol-specified radiation therapy. Five patients had to stop the protocol therapy, 2 patients with pulmonary emboli, and 1 patient each with a Grade 2 central nervous system hemorrhage, Grade 4 pancytopenia, and wound dehiscence requiring surgical intervention. All 5 patients ultimately finished the radiation therapy. After radiation therapy, 3 patients had progressive disease, 2 had severe fatigue and decreased performance status, 1 patient had a colonic perforation, and 1 had a rectal fissure; these 7 patients therefore did not proceed with the protocol-specified adjuvant temozolomide, bevacizumab, and irinotecan. However, 113 patients (90%) were able to continue on study. CONCLUSIONS:
|
Authors | James J Vredenburgh, Annick Desjardins, John P Kirkpatrick, David A Reardon, Katherine B Peters, James E Herndon 2nd, Jennifer Marcello, Leighann Bailey, Stevie Threatt, John Sampson, Allan Friedman, Henry S Friedman |
Journal | International journal of radiation oncology, biology, physics
(Int J Radiat Oncol Biol Phys)
Vol. 82
Issue 1
Pg. 58-66
(Jan 01 2012)
ISSN: 1879-355X [Electronic] United States |
PMID | 21036490
(Publication Type: Clinical Trial, Phase II, Journal Article)
|
Copyright | Copyright © 2012 Elsevier Inc. All rights reserved. |
Chemical References |
- Angiogenesis Inhibitors
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents, Alkylating
- Glucocorticoids
- Bevacizumab
- Irinotecan
- Dacarbazine
- Dexamethasone
- Camptothecin
- Temozolomide
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Angiogenesis Inhibitors
(administration & dosage, adverse effects)
- Antibodies, Monoclonal, Humanized
(administration & dosage, adverse effects)
- Antineoplastic Agents, Alkylating
(administration & dosage, adverse effects)
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage, adverse effects)
- Bevacizumab
- Brain Neoplasms
(pathology, therapy)
- Camptothecin
(administration & dosage, adverse effects, analogs & derivatives)
- Chemoradiotherapy
(methods)
- Craniotomy
- Dacarbazine
(administration & dosage, adverse effects, analogs & derivatives)
- Dexamethasone
(administration & dosage)
- Dose Fractionation, Radiation
- Drug Administration Schedule
- Female
- Glioblastoma
(pathology, therapy)
- Glucocorticoids
(administration & dosage)
- Humans
- Injections, Intravenous
- Irinotecan
- Magnetic Resonance Imaging
- Male
- Middle Aged
- Temozolomide
- Tumor Burden
- Young Adult
|